SLC6A2 and metabolic dysfunction-associated steatohepatitis: The 514 predicted targets were intersected with 293 DEGs to gain 11 targets of POL in treating NASH (N&P: IL-6, FOS, SCD, CXCL2, PTGS2, IKBKG, PCK1, ALDH3A1, SLC6A2, ACHE, and CHRM3) (Figures 3C,E).